CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


monthly serologic IgM/G testWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug2797 daily syndromic surveillance Wiki 1.00
drug1936 Psychiatric counseling Wiki 1.00

Correlated MeSH Terms (1)


Name (Synonyms) Correlation
D018352 Coronavirus Infections NIH 0.04

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials


1 A Prospective Study of COVID-19 Using Real-Time Syndromic Surveillance, Scheduled At-home Serologic Testing, and Electronic Health Records

The purpose of this research is to collect information about coronavirus exposures, symptoms, and health care visits due to the among Atrium Health clients and health care workers. Participation in this study will involve completing a daily questionnaire which covers participants coronavirus illness history or symptoms, health care seeking behaviors and treatments, contact with other sick people, and for health care workers, their use of personal protective equipment.

NCT04361123 Coronavirus COVID Other: daily syndromic surveillance Diagnostic Test: monthly serologic IgM/G test
MeSH:Coronavirus Infections

Primary Outcomes

Description: Percent of volunteers who are 2019-nCoV Ab test positive

Measure: Seroprevalence of SARS-CoV-2 infection in the general population of North Carolina

Time: baseline

Description: Percent of volunteers who are 2019-nCoV Ab test positive

Measure: Seroprevalence of SARS-CoV-2 infection among health care workers of North Carolina

Time: baseline

Secondary Outcomes

Measure: Cumulative incidence of SARS-CoV-2 infection

Time: 12 month

Measure: Monthly incidence of SARS-CoV-2 infection

Time: Month 1 thru month 12

Measure: Stratified incidence of SARS-CoV-2 infection by age group

Time: Month 1 thru month 12

Measure: Stratified incidence of SARS-CoV-2 infection by sex

Time: Month 1 thru month 12

Measure: Stratified incidence of SARS-CoV-2 by season

Time: Month 1 thru month 12

Measure: Stratified incidence of SARS-CoV-2 infection by geographic area (zip code)

Time: Month 1 thru month 12

Measure: Stratified incidence of SARS-CoV-2 infection by preexisting comorbidities

Time: Month 1 thru month 12

Measure: Stratified incidence of SARS-CoV-2 infection by COVID-2 contacts

Time: Month 1 thru month 12

Measure: •Stratified incidence of SARS-CoV-2 infection by use of personal protective equipment (PPE) by health workers

Time: Month 1 thru month 12

Measure: Relative risk of SARS-CoV-2 infection by age group

Time: Month 1 thru month 12

Measure: Relative risk of SARS-CoV-2 infection by sex

Time: Month 1 thru month 12

Measure: Relative risk of SARS-CoV-2 infection by season

Time: Month 1 thru month 12

Measure: Relative risk of SARS-CoV-2 infection by geographic area (zip code)

Time: Month 1 thru month 12

Measure: Relative risk of SARS-CoV-2 infection by preexisting comorbidities

Time: Month 1 thru month 12

Measure: Relative risk of SARS-CoV-2 infection by COVID-2 contacts

Time: Month 1 thru month 12

Measure: Relative risk of SARS-CoV-2 infection by use of PPE by health workers

Time: Month 1 thru month 12

Measure: Incidence of sequelae

Time: Month 1 thru month 12


No related HPO nodes (Using clinical trials)